ContextLogic Inc - Ordinary Shares - Class A

ContextLogic Inc - Ordinary Shares - Class A

LOGC

Get informed when a big investor buys or sells

+ Follow
Market Cap$518.58M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
ContextLogic Inc - Ordinary Shares - Class AContextLogic Inc - Ordinary Shares - Class A-31.5-3%11.30.3
$0.00

Current Fair Value

100% downside

Overvalued by 100% based on the discounted cash flow analysis.

Share Statistics

Market cap$518.58 Million
Enterprise Value$717.48 Million
Dividend Yield$- (-)
Earnings per Share$-1.09
Beta2.02
Outstanding Shares45,737,000

Return

Return on Equity2.81%ROE
Return on Assets2.13%
Return on Invested Capital-2.65%

Valuation & Multiples

P/E Ratio-31.5P/E Ratio
PEG-630PEG
Price to Sales11.31Price to Sales
Price to Book Ratio0.71Price to Book Ratio
Enterprise Value to Revenue10.87
Enterprise Value to EBIT-28.57
Enterprise Value to Net Income34
Total Debt to Enterprise0.29
Debt to Equity0.29Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
August 13, 2026
EPS Estimate
$-0.04
Average shareholder expectation
Revenue Estimate
$33.60 M
Average shareholder expectation

Next Earnings Call

Expected Date
November 3, 2026
EPS Estimate
$-0.04
Average shareholder expectation
Revenue Estimate
$23.31 M
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.00000%
Total Calls-
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %2.39%▲ 2.22%
Total Invested$4.85M▲ 1828.26%
Investors Holding2▲ 1.00%

ESG Score

No data

About LogicBio Therapeutics Inc

39 employees
CEO: Frederic Chereau

LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood. The company's proprietary GeneRide™ platform is a...